Switching Anti-TNF-Alpha Agents in Rheumatoid Arthritis (RA)
Status:
Terminated
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
Rheumatoid Arthritis (RA) is a systemic inflammatory autoimmune disorder that leads to
inflammation and progressive joint damage affecting 2.5 million people in the United States.
The primary purpose of this study is to determine the effectiveness of switching to an
alternative Tumor Necrosis Factor (TNF) alpha inhibitor in comparison to continuing treatment
with an existing TNF-alpha inhibitor in adults suffering from RA in a setting of inadequate
clinical response to etanercept or adalimumab.
Phase:
Phase 4
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)